NASDAQ:ERYP

ERYTECH Pharma Stock Forecast, Price & News

$5.86
-0.53 (-8.29 %)
(As of 09/21/2021 12:56 PM ET)
Add
Compare
Today's Range
$5.86
$6.06
50-Day Range
$4.11
$6.47
52-Week Range
$4.10
$13.00
Volume1,528 shs
Average Volume409,729 shs
Market Capitalization$160.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56
30 days | 90 days | 365 days | Advanced Chart
Receive ERYP News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter.


ERYTECH Pharma logo

About ERYTECH Pharma

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.77 out of 5 stars

Medical Sector

1279th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

185th out of 193 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ERYTECH Pharma (NASDAQ:ERYP) Frequently Asked Questions

What stocks does MarketBeat like better than ERYTECH Pharma?

Wall Street analysts have given ERYTECH Pharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ERYTECH Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ERYTECH Pharma?

ERYTECH Pharma saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 34,500 shares, a drop of 70.5% from the August 15th total of 116,900 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the shares of the company are short sold.
View ERYTECH Pharma's Short Interest
.

When is ERYTECH Pharma's next earnings date?

ERYTECH Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, September 21st 2021.
View our earnings forecast for ERYTECH Pharma
.

How has ERYTECH Pharma's stock been impacted by COVID-19?

ERYTECH Pharma's stock was trading at $5.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ERYP stock has increased by 13.5% and is now trading at $5.95.
View which stocks have been most impacted by COVID-19
.

Who are ERYTECH Pharma's key executives?

ERYTECH Pharma's management team includes the following people:
  • Gil Beyen, Chief Executive Officer & Director
  • Eric Soyer, Chief Operating & Financial Officer
  • Stewart Craig, Chief Technical Officer
  • Iman El-Hariry, Chief Medical Officer
  • Jérôme Bailly, Chief Quality Officer & Deputy General Manager

Who are some of ERYTECH Pharma's key competitors?

What other stocks do shareholders of ERYTECH Pharma own?

When did ERYTECH Pharma IPO?

(ERYP) raised $125 million in an IPO on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.

What is ERYTECH Pharma's stock symbol?

ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP."

Who are ERYTECH Pharma's major shareholders?

ERYTECH Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include BVF Inc. IL (4.98%).

Which institutional investors are buying ERYTECH Pharma stock?

ERYP stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL.

How do I buy shares of ERYTECH Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ERYTECH Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $5.95.

How much money does ERYTECH Pharma make?

ERYTECH Pharma has a market capitalization of $162.55 million and generates $4.25 million in revenue each year. The company earns $-83,730,000.00 in net income (profit) each year or ($4.55) on an earnings per share basis.

How many employees does ERYTECH Pharma have?

ERYTECH Pharma employs 206 workers across the globe.

What is ERYTECH Pharma's official website?

The official website for ERYTECH Pharma is www.erytech.com.

Where are ERYTECH Pharma's headquarters?

ERYTECH Pharma is headquartered at 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008.

How can I contact ERYTECH Pharma?

ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at (347) 874-4438 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.